Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer's Disease: From Clinical Trials to Real-World Practice

TL;DR

• ARIA is an expected side effect of anti-amyloid therapy, not just a complication — it reflects the drug clearing amyloid from cerebral vessels.
• Two phenotypes: ARIA-E (edema) and ARIA-H (microhemorrhages/siderosis), detected on FLAIR and SWI/T2* respectively.
• APOE ε4 is the strongest risk factor (highest in homozygotes); most events are asymptomatic and resolve on their own.
• MRI is now a safety-monitoring tool, not just diagnostic — baseline and serial scans are essential, especially early in treatment.
• The next frontier is real-world evidence: standardized imaging + AI-assisted detection could turn ARIA into a reproducible, quantitative biomarker.
  ‍

‍

Introduction

The approval of anti-amyloid monoclonal antibodies has fundamentally changed the management of patients with early Alzheimer's disease. For the first time, clinicians have therapies designed to target amyloid pathology, although the precise role of amyloid in driving disease progression remains the subject of ongoing debate. Alongside these advances, however, a new clinical challenge has emerged: amyloid-related imaging abnormalities (ARIA).  

ARIA has rapidly become part of routine neurological and radiological practice. The recent update from the Alzheimer's Association ARIA Workgroup (1) provides practical recommendations for recognizing, monitoring, and managing ARIA as these therapies gain broader clinical adoption. Beyond its immediate clinical implications, the report also highlights the importance of high-quality real-world evidence (RWE) to better understand the safety and optimal use of anti-amyloid therapies outside the controlled environment of clinical trials.

‍

ARIA: A Pharmacodynamic Effect

ARIA is recognized as the most characteristic adverse effect of amyloid-targeting therapies and is also considered an expected pharmacodynamic consequence of amyloid removal. As monoclonal antibodies facilitate clearance of amyloid-β from cerebral vessels and parenchyma, temporary changes in vascular integrity may occur, leading to characteristic MRI findings.

Two imaging phenotypes are recognized. ARIA-E consists of vasogenic edema and sulcal effusions, while ARIA-H includes cerebral microhemorrhages and superficial siderosis. Although distinct, these manifestations likely represent different expressions of the same underlying vascular response and may occur simultaneously in some patients.

‍

Why MRI Is Now Central to Alzheimer's Therapeutics

One of the most notable consequences of anti-amyloid therapy is the expanding role of brain MRI throughout the treatment pathway.

Historically, brain MRI in Alzheimer's disease primarily served diagnostic purposes, excluding alternative etiologies such as cerebrovascular disease, tumors, or hydrocephalus. Today, imaging has acquired an additional function as an active safety monitoring tool.

Brain MRI is indispensable both before and during treatment. Baseline examinations identify imaging features that may increase ARIA risk, while serial follow-up studies detect new abnormalities before clinical symptoms develop.

Different MRI sequences provide complementary information. Fluid-attenuated inversion recovery (FLAIR) is the primary sequence for detecting ARIA-E, whereas susceptibility-sensitive techniques such as susceptibility-weighted imaging (SWI) or T2*-weighted gradient-echo imaging are essential for identifying ARIA-H, including cerebral microhemorrhages and superficial siderosis.

Because treatment decisions frequently depend on subtle imaging changes, the Workgroup strongly advocates standardized acquisition protocols and consistent radiological interpretation across institutions.

‍

ARIA-E and ARIA-H: The Two Imaging Phenotypes

The two phenotypes differ in their findings and their optimal MRI sequence.

ARIA-E: vasogenic edema and sulcal effusions; detected primarily with FLAIR.

ARIA-H: cerebral microhemorrhages and superficial siderosis; detected with SWI or T2*-weighted gradient-echo imaging.

Although distinct, both likely represent different expressions of the same vascular response. Some patients may develop both at once.

Clinical Best Practices: Risk and Management

Not every patient carries the same likelihood of developing ARIA, so identifying greater risk is critical.

Among currently recognized risk factors, carriage of the APOE ε4 allele remains the strongest predictor, particularly in homozygotes. Notably, donanemab and lecanemab are approved regardless of patients’ apolipoprotein E (APOE) ε4 allele carrier status in many countries, including the United States, Japan, and China.

Baseline MRI findings also contribute to risk stratification. Pre-existing cerebral microhemorrhages, superficial siderosis, and imaging evidence suggestive of cerebral amyloid angiopathy all increase the probability of treatment-associated ARIA.

Emerging ARIA risk factors include untreated hypertension, higher baseline blood pressure, high baseline amyloid PET burden and elevated phosphorylated tau (p-tau) in cerebrospinal fluid. Importantly, the concomitant use of anticoagulants, or the administration of thrombolytics in patients taking anti-amyloid therapy can increase the risk of severe ARIA and vascular complications.  

ARIA occurs most commonly during the early phases of treatment, particularly while doses are being escalated. This predictable temporal pattern supports scheduled surveillance imaging during the initial months of therapy.

Fortunately, most ARIA events are asymptomatic, detected only through routine MRI surveillance, and resolve without permanent neurological sequelae. Nevertheless, symptomatic cases require prompt recognition and appropriate management. Possible symptoms include headache, confusion, visual symptoms, gait disturbances, or focal neurological deficits that may mimic an acute stroke, such as weakness, numbness, or speech difficulties.

Clinical management is largely guided by both imaging severity and symptomatology. Mild asymptomatic ARIA can often be managed with continued treatment and closer monitoring, whereas symptomatic ARIA or moderate-to-severe imaging abnormalities generally require temporary interruption of therapy until radiographic improvement is demonstrated. Because the ARIA severity spectrum is broad, and differential diagnosis is paramount for management, the Workgroup recommends that only practitioners with sufficient clinical specialty background and resources for ARIA management should prescribe amyloid-targeting therapies.

From Clinical Trials to Real-World Evidence

While randomized clinical trials established the efficacy and safety profiles of anti-amyloid therapies, the Workgroup acknowledges that many unanswered questions remain.

Trial populations are necessarily selective, often excluding patients with substantial vascular comorbidity, extensive cerebral amyloid angiopathy, anticoagulant use, or other characteristics frequently encountered in everyday practice. Consequently, clinicians now face patient populations that likely differ from those enrolled in pivotal studies.

Real-world data help expand the breadth of evidence on the population receiving anti-amyloid monoclonal antibodies. Large-scale longitudinal datasets integrating electronic health records, neuroimaging, genetics, medication exposure, and clinical outcomes can provide insights that clinical trials alone cannot. They offer opportunities to evaluate ARIA incidence across broader patient populations, further characterize imaging patterns, and better understand recurrence, long-term outcomes, and management strategies.

‍

Imaging Data Beyond Surveillance

The increasing use of serial MRI also creates an unprecedented opportunity for imaging-based RWE.

Routine clinical care now generates longitudinal neuroimaging datasets that include baseline examinations, surveillance MRIs, and follow-up studies after ARIA resolution. When combined with structured clinical information, these imaging repositories can answer questions extending well beyond treatment safety.

Examples include identifying imaging biomarkers that predict ARIA before treatment begins, developing automated methods to detect subtle ARIA changes, quantifying lesion evolution over time, and evaluating how imaging findings correlate with neurological symptoms and treatment continuation.

Artificial intelligence may further enhance these efforts by improving lesion detection, standardizing ARIA grading, and reducing inter-reader variability across institutions.

Such approaches have the potential to transform ARIA from a largely qualitative imaging diagnosis into a reproducible, quantitative biomarker suitable for multicenter research and routine clinical practice.

‍

Looking Ahead

ARIA has rapidly evolved from a research observation into a routine component of Alzheimer's disease management.  

The Alzheimer's Association ARIA Workgroup provides an important framework for safe implementation of anti-amyloid therapies. For neurologists and radiologists, familiarity with its imaging manifestations, risk factors, and management strategies is now essential.  

The report stresses the need for standardization, including consistent terminology, harmonized MRI protocols, and structured radiology reporting. Standardization will not only improve patient care but also create the foundation for robust multicenter RWE research.

Long-term clinical outcomes associated with ARIA remain to be elucidated. While there is concern over possible adverse clinical effects, emerging evidence suggests that ARIA-E, particularly when asymptomatic, may be associated with more effective amyloid clearance and potentially better clinical outcomes. The Workgroup emphasized the importance of continued real-world data collection, as the next generation of evidence will increasingly come from routine clinical practice.

‍

Segmed Perspective

‍‍As anti-amyloid therapies move into routine clinical practice, the need for robust real-world imaging evidence continues to grow. While randomized clinical trials established the efficacy and safety of these therapies, many questions regarding ARIA incidence, recurrence, long-term outcomes, and imaging biomarkers will only be answered through large-scale real-world datasets.

At Segmed, we believe imaging is not simply another data modality it is the clinical reference standard for understanding treatment response and safety in neurology. By combining longitudinal brain MRI with structured clinical, molecular, and treatment data, regulatory-grade multimodal datasets can support research into ARIA risk prediction, standardized imaging assessment, and AI-driven tools that improve monitoring across diverse healthcare settings.

As Alzheimer's therapies continue to evolve, high-quality real-world imaging data will play an increasingly important role in generating evidence that complements clinical trials and supports better patient care.

‍

‍

Frequented Asked Questions - F.A.Q.

‍

What is ARIA?

Amyloid-related imaging abnormalities (ARIA) are MRI findings associated with anti-amyloid monoclonal antibody therapies used to treat early Alzheimer's disease. ARIA includes two primary imaging patterns: ARIA-E (vasogenic edema and sulcal effusions) and ARIA-H (cerebral microhemorrhages and superficial siderosis).

‍

Why is MRI required during anti-amyloid therapy?

MRI is essential for both baseline risk assessment and ongoing safety monitoring. Baseline imaging helps identify patients at increased risk of ARIA, while scheduled follow-up MRI examinations detect new imaging abnormalities before clinical symptoms develop.

‍

Who is at highest risk of developing ARIA?

The strongest known risk factor is carriage of the APOE ε4 allele, particularly in homozygous individuals. Additional risk factors include pre-existing cerebral microhemorrhages, superficial siderosis, cerebral amyloid angiopathy, untreated hypertension, high amyloid burden, elevated cerebrospinal fluid phosphorylated tau, and concomitant anticoagulant therapy.

‍

Are most ARIA events symptomatic?

No. Most ARIA events are asymptomatic and are detected only through routine MRI surveillance. When symptoms occur, they may include headache, confusion, visual disturbances, gait abnormalities, or focal neurological deficits.

‍

Why is real-world evidence important for ARIA research?

Clinical trials enrolled carefully selected patient populations. Real-world evidence expands understanding by evaluating ARIA across broader and more diverse populations, providing insights into incidence, recurrence, long-term outcomes, imaging biomarkers, and treatment management in routine clinical practice.

‍

Reference

van Etten ES, Mahinrad S, Grill JD, Salloway S, Atri A, Cogswell PM, et al. Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup. Alzheimers Dement. 2026;22:e71361. doi:10.1002/alz.7136

‍

Related Resources

Alzheimer's Disease: Power of Real-World Imaging Data (RWiD)
‍FDA Expectations for Real-World Imaging Data: Building Regulatory-Grade RWE.
‍Multimodal Data Pipelines in Pharma Research: Connecting Imaging, Clinical, and Molecular Data.
RWID Multimodal · Pre-built research cohort